Item | 6m 2024 | 6m 2025 | Change |
---|---|---|---|
Revenues | 2,890.76 | 3,148.70 | 8.9 % |
Gross Income | 931.47 | 1,061.99 | 14.0 % |
Operating Income | 180.46 | 169.59 | (6.0 %) |
Net Income | 132.31 | 118.95 | (10.1 %) |
Average Shares | 1,143.00 | 1,143.00 | - |
Earnings Per Share before unusual items (Riyals) | 0.12 | 0.10 | (10.1 %) |
EPS (Riyal) | 0.12 | 0.10 | (10.1 %) |
Before minority interest, H1 2025 net earnings reached SAR 116.2 million, compared with SAR 135.6 million a year before.
Total operating expenses increased in H1 2025 to SAR 892.4 million from SAR 751 million in H1 2024, due to additional costs from the retail pharma and distribution businesses, which were not included in H1 2024.
This was in addition to the full-period impact of store operating costs for BinDawood and Danube stores opened during 2024, and new BinDawood, Danube and Retail Pharma stores launched in H1 2025.
The company also cited higher expenses from integrating pharmacy sections inside key BinDawood and Danube stores., along with increased staffing, utilities and logistics costs associated with new and expanded store operations.
Item | Q2 2024 | Q2 2025 | Change |
---|---|---|---|
Revenues | 1,417.84 | 1,474.31 | 4.0 % |
Gross Income | 480.43 | 533.29 | 11.0 % |
Operating Income | 98.89 | 79.38 | (19.7 %) |
Net Income | 72.65 | 51.83 | (28.7 %) |
Average Shares | 1,143.00 | 1,143.00 | - |
Earnings Per Share before unusual items (Riyal) | 0.06 | 0.05 | (28.7 %) |
EPS (Riyal) | 0.06 | 0.05 | (28.7 %) |
Item | Q1 2025 | Q2 2025 | Change |
---|---|---|---|
Revenues | 1,674.39 | 1,474.31 | (11.9 %) |
Gross Income | 528.70 | 533.29 | 0.9 % |
Operating Income | 90.21 | 79.38 | (12.0 %) |
Net Income | 67.12 | 51.83 | (22.8 %) |
Average Shares | 1,143.00 | 1,143.00 | - |
Earnings Per Share before unusual items (Riyal) | 0.06 | 0.05 | (22.8 %) |
EPS (Riyal) | 0.06 | 0.05 | (22.8 %) |
In Q2 2025, net profit dropped 28.7% to SAR 5.183 million from SAR 72.65 million a year earlier.
The second-quarter net earnings dropped by 22.8% from SAR 67.12 million in Q1 2025.
Shareholders’ equity, excluding minority interest, rose to SAR 1.41 billion as of June 30, 2025, from SAR 1.40 billion a year earlier.
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: